Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
13.67
-0.64 (-4.47%)
At close: Jul 25, 2025, 4:00 PM
13.87
+0.20 (1.46%)
After-hours: Jul 25, 2025, 7:48 PM EDT

Company Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).

The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease.

The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.

Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.
Denali Therapeutics logo
CountryUnited States
Founded2013
IPO DateDec 8, 2017
IndustryBiotechnology
SectorHealthcare
Employees422
CEORyan Watts

Contact Details

Address:
161 Oyster Point Boulevard
South San Francisco, California 94080
United States
Phone650 866 8547
Websitedenalitherapeutics.com

Stock Details

Ticker SymbolDNLI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001714899
CUSIP Number24823R105
ISIN NumberUS24823R1059
Employer ID46-3872213
SIC Code2836

Key Executives

NamePosition
Dr. Ryan J. Watts Ph.D.Co-Founder, President, Chief Executive Officer and Director
Dr. Alexander O. Schuth M.D.Co-Founder, Chief Financial Officer, Chief Operating Officer and Secretary
Dr. Marc Tessier-Lavigne Ph.D.Co-Founder and Independent Director
Dr. Carole Ho M.D.Chief Medical Officer and Head of Development
Dr. Dana AndersenChief Technical and Manufacturing Officer
Joe Lewcock Ph.D.Chief Scientific Officer
Chris Walsh J.D.General Counsel
Cindy DunkleChief People Officer
Katie PengChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jul 9, 2025144Filing
Jul 7, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 17, 2025ARSFiling
Apr 17, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2025DEF 14AOther definitive proxy statements
Apr 17, 2025SCHEDULE 13G/AFiling
Apr 2, 20258-KCurrent Report